Atlas Trials

A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants

Clinical trial NCT04085289 · COMPLETED

Trial details

NCT number
NCT04085289
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2019-11-20
Primary completion
2020-05-21
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.